Literature DB >> 15302676

Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury.

Danielle G Souza1, Riccardo Bertini, Angelica T Vieira, Fernando Q Cunha, Steve Poole, Marcello Allegretti, Francesco Colotta, Mauro M Teixeira.   

Abstract

1. Neutrophils are thought to play a major role in the mediation of reperfusion injury. CXC chemokines are known inducers of neutrophil recruitment. Here, we assessed the effects of Repertaxin, a novel low molecular weight inhibitor of human CXCL8 receptor activation, on the local, remote and systemic injuries following intestinal ischaemia and reperfusion (I/R) in the rat. 2. Pre-incubation of rat neutrophils with Repertaxin (10(-11)-10(-6) m) inhibited the chemotaxis of neutrophils induced by human CXCL8 or rat CINC-1, but not that induced by fMLP, PAF or LTB(4), in a concentration-dependent manner. Repertaxin also prevented CXCL8-induced calcium influx but not CXCL8 binding to purified rat neutrophils. 2. In a model of mild I/R injury (30 min of ischaemia and 30 min of reperfusion), Repertaxin dose-dependently (3-30 mg kg(-1)) inhibited the increase in vascular permeability and neutrophil influx. Maximal inhibition occurred at 30 mg kg(-1). 4. Following severe I/R injury (120 min of ischaemia and 120 min of reperfusion), Repertaxin (30 mg kg(-1)) markedly prevented neutrophil influx, the increase in vascular permeability both in the intestine and the lungs. Moreover, there was prevention of haemorrhage in the intestine of reperfused animals. 5. Repertaxin effectively suppressed the increase in tissue (intestine and lungs) and serum concentrations of TNF-alpha and the reperfusion-associated lethality. 6. For comparison, we also evaluated the effects of an anti-CINC-1 antibody in the model of severe I/R injury. Overall, the antibody effectively prevented tissue injury, systemic inflammation and lethality. However, the effects of the antibody were in general of lower magnitude than those of Repertaxin. 7. In conclusion, CINC-1 and possibly other CXC chemokines, acting on CXCR2, have an important role during I/R injury. Thus, drugs, such as Repertaxin, developed to block the function of the CXCR2 receptor may be effective at preventing reperfusion injury in relevant clinical situations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302676      PMCID: PMC1575259          DOI: 10.1038/sj.bjp.0705862

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  47 in total

Review 1.  The neutrophil as a mediator of myocardial ischemia-reperfusion injury: time to move on.

Authors:  Gary F Baxter
Journal:  Basic Res Cardiol       Date:  2002-07       Impact factor: 17.165

Review 2.  Anti-adhesion therapy.

Authors:  C J Cornejo; R K Winn; J M Harlan
Journal:  Adv Pharmacol       Date:  1997

3.  Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury.

Authors:  Danielle G Souza; Adriana C Soares; Vanessa Pinho; Humberto Torloni; Luiz F L Reis; Mauro M Teixeira; Adriana A M Dias; Mauro T Martins
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

4.  Effects of a monoclonal antibody directed against P-selectin after myocardial ischemia and reperfusion.

Authors:  D J Lefer; D M Flynn; A J Buda
Journal:  Am J Physiol       Date:  1996-01

5.  TNF-alpha potentiates oxidant and reperfusion-induced endothelial cell injury.

Authors:  R R Gilmont; A Dardano; J S Engle; B S Adamson; M J Welsh; T Li; D G Remick; D J Smith; R S Rees
Journal:  J Surg Res       Date:  1996-02-15       Impact factor: 2.192

6.  Protective effects of anti-neutrophil antibody against myocardial ischemia/reperfusion injury in rats.

Authors:  T Kohtani; Y Abe; M Sato; K Miyauchi; K Kawachi
Journal:  Eur Surg Res       Date:  2002 Jul-Aug       Impact factor: 1.745

7.  Cytokine-induced neutrophil chemoattractant 1 (CINC-1) mediates the sympathetic component of inflammatory mechanical hypersensitivitiy in rats.

Authors:  Berenice B Lorenzetti; Fabiane H Veiga; Claudio A Canetti; Stephen Poole; Fernando Q Cunha; Sérgio H Ferreira
Journal:  Eur Cytokine Netw       Date:  2002 Oct-Dec       Impact factor: 2.737

Review 8.  Renal ischaemia--reperfusion injury.

Authors:  S C Weight; P R Bell; M L Nicholson
Journal:  Br J Surg       Date:  1996-02       Impact factor: 6.939

9.  Single-cell analysis of macrophage chemotactic protein-1-regulated cytosolic Ca2+ increase in human adherent monocytes.

Authors:  C Bizzarri; R Bertini; P Bossù; S Sozzani; A Mantovani; J Van Damme; A Tagliabue; D Boraschi
Journal:  Blood       Date:  1995-09-15       Impact factor: 22.113

10.  IL-1 beta primes IL-8-activated human neutrophils for elastase release, phospholipase D activity, and calcium flux.

Authors:  L Brandolini; R Bertini; C Bizzarri; R Sergi; G Caselli; D Zhou; M Locati; S Sozzani
Journal:  J Leukoc Biol       Date:  1996-03       Impact factor: 4.962

View more
  34 in total

1.  Botulinum Toxin Confers Radioprotection in Murine Salivary Glands.

Authors:  Youssef H Zeidan; Nan Xiao; Hongbin Cao; Christina Kong; Quynh-Thu Le; Davud Sirjani
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-12-29       Impact factor: 7.038

2.  Role of CXCR2 and TRPV1 in functional, inflammatory and behavioural changes in the rat model of cyclophosphamide-induced haemorrhagic cystitis.

Authors:  Fabiana N Dornelles; Edinéia L Andrade; Maria M Campos; João B Calixto
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

3.  LPS preconditioning ameliorates intestinal injury in a rat model of hemorrhagic shock.

Authors:  Ruiming Chang; Yingyan Wang; Jianxing Chang; Liqiang Wen; Zhipeng Jiang; Tao Yang; Kai Yu
Journal:  Inflamm Res       Date:  2014-05-20       Impact factor: 4.575

4.  Interleukin-8 mediates neutrophil-endothelial interactions in pig-to-human xenogeneic models.

Authors:  Beth M French; Selin Sendil; Krishna Mohan Sepuru; Jolene Ranek; Lars Burdorf; Donald Harris; Emily Redding; Xiangfei Cheng; Christopher T Laird; Yuming Zhao; Benjamin Cerel; Krishna Rajarathnam; Richard N Pierson; Agnes M Azimzadeh
Journal:  Xenotransplantation       Date:  2018-02-09       Impact factor: 3.907

5.  Reparixin, a CXCR1/2 inhibitor in islet allotransplantation.

Authors:  Rena L Pawlick; John Wink; Andrew R Pepper; Antonio Bruni; Nasser Abualhassen; Yasmin Rafiei; Boris Gala-Lopez; Mariusz Bral; A M James Shapiro
Journal:  Islets       Date:  2016-06-21       Impact factor: 2.694

6.  Maxadilan, the Lutzomyia longipalpis vasodilator, drives plasma leakage via PAC1-CXCR1/2-pathway.

Authors:  Erik Svensjö; Elvira M Saraiva; Rafael Silveira Amendola; Christina Barja-Fidalgo; Marcelo T Bozza; Ethan A Lerner; Mauro M Teixeira; Julio Scharfstein
Journal:  Microvasc Res       Date:  2011-10-19       Impact factor: 3.514

Review 7.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

8.  The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice.

Authors:  Danielle G Souza; Flavio A Amaral; Caio T Fagundes; Fernanda M Coelho; Rosa M E Arantes; Lirlandia P Sousa; Martin M Matzuk; Cecília Garlanda; Alberto Mantovani; Adriana A Dias; Mauro M Teixeira
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

9.  Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice.

Authors:  A Zarbock; M Allegretti; K Ley
Journal:  Br J Pharmacol       Date:  2008-06-30       Impact factor: 8.739

10.  A crucial role for TNF-alpha in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5.

Authors:  S M Vieira; H P Lemos; R Grespan; M H Napimoga; D Dal-Secco; A Freitas; T M Cunha; W A Verri; D A Souza-Junior; M C Jamur; K S Fernandes; C Oliver; J S Silva; M M Teixeira; F Q Cunha
Journal:  Br J Pharmacol       Date:  2009-08-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.